

May 30, 2024

Contents

Clinical Profile Documentation	2
Additions.....	2
Lab Analytes & Panels	2
Additions.....	2
Medications.....	3
Updates	3
Regimen Library.....	4
Additions.....	4
Pemrydi RTU	4
Updates	4
Research.....	5
Updates	5
Billing & HCPCS Codes	6
Updates	6
NDC to HCPCS Crosswalk	7
Additions.....	7

Clinical Profile Documentation

Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

- **HER-2/neu status** is no longer available for **Bile Duct Cancer (Parent)** and **Gallbladder Cancer**.
- **HER-2/neu Value-ISH** is no longer available for **Bile Duct Cancer (Parent)** and **Gallbladder Cancer**.
- **HER2/neu results (via NGS, ISH, etc.)** is now available for **Bile Duct Cancer (Parent)** and **Gallbladder Cancer** with the following documentation points:
 - Positive
 - Negative
 - Unknown

Lab Analytes & Panels

Additions

- A - Beta-amyloid 42/40
- Adenosine deaminase pleural fluid, U/L
- Albumin, random urine w/o creatinine panel
- Aldosterone urine, ug/L
- Apolipoprotein E genotype, comments
- Apolipoprotein E genotype, methods
- Apolipoprotein E genotype, references
- ATN Profile panel
- ATN SUMMARY [1]
- B. quintana IgG titer panel
- Bartonella quintana AB, IgG, screen panel
- Bartonella quintana AB, IgM, screen panel
- Beta-amyloid 40
- Beta-amyloid 42
- Celiac disease antibody evaluation panel
- CSF fungus culture
- CSF fungus culture panel
- Cytomegalovirus (CMV) Ab. IgM panel
- ENA screen interpretation
- Endomysial antibody, IgA panel

- Ferritin, serum, ug/L
- Fungus culture, blood
- Fungus culture, blood panel
- Hemoglobin variant by mass spectrometry panel
- Hepatitis delta virus, qual
- Hepatitis delta virus panel
- Hepatocellular carcinoma panel
- Histoplasma antibody by immunodiffusion panel
- HSV 2 IgG result
- Immune complex, EU/mL
- Information:
- Intrinsic factor blocking antibody panel
- JO-1 antibody, CU
- Medical device aerobic culture
- Medical device aerobic culture panel
- Metanephrines fract, free, blood panel
- Myeloma, FISH, fixed cells
- Myeloma, FISH, fixed cells panel
- N -- NfL, plasma
- Ova + parasite exam, urine
- Sjogren's panel with rheumatoid factor and ANA, IFA with reflex
- Sjogren's panel with rheumatoid factor and ANA, IFA with reflex panel
- SSB antibody, CU
- T -- p-tau181
- T-transglutaminase (tTG), serum IgG, CU
- Thalassemia summary interpretation
- Thalassemia summary review by
- Treponema pallidum ab panel
- WBC/NUC cells, fluid, %
- Wright stain smear

Medications

Updates

Medication	Update
IGM-8444 invest IV	New Alias available: Aplitabart invest
ALLO-501A invest IV	New Form available: 20x10e6 cells/mL solution
BA3071 invest IV	Updated Form: 40 mg/mL solution
ART6043 invest Oral	New Form available: 200 mg tablet
ACE2016 invest IV	New drug

Medication	Update
ABT 234 or Pembrolizumab invest IV	New drug
Naporafenib invest Oral	New Forms available: 50 mg tablet and 75 mg tablet
KSQ-4279 invest Oral	Renamed to RO76230066 invest Oral
Ofatumumab IV	Updated instructions

Regimen Library

Additions

Pemrydi RTU

To improve ease of ordering, a new unchecked Pemrydi RTU (Pemetrexed IV) order has been added to all regimen templates containing Pemetrexed IV.

The following regimens have been added into the library.

Regimen Name	Diagnosis
Epirubicin D1,2 + Ifosfamide D1-5 Q21D	Sarcoma, Soft Tissue (Parent)
Gemcitabine D1,8,15 + Trastuzumab IV D1,8,15,22 Q28D	Breast Cancer
Pembrolizumab (Dose Banding) + Paclitaxel D1,8,15,22,29,36 + Carboplatin D1,8,15,22,29,36 Q42D fb Pembrolizumab (Dose Banding) + Doxorubicin + Cyclophosphamide (AC) Q42D	Breast Cancer
Pemivibart (Pemgarda) (COVID-19 Pre-Exposure Prophylaxis)	All Problems
Talquetamab-tgvs SQ Option D1,3,5,7 (Biweekly Dosing: Initial)	Multiple Myeloma (MM)
Teclistamab-cqyv SQ Option D1,3,5 (Initial)	Multiple Myeloma (MM)
VTD-PACE	Multiple Myeloma (MM)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Bile Duct Cancer (Parent)
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Fallopian Tube Cancer
- Gallbladder Cancer
- Head and Neck Cancer (Parent)
- Leukemia, Chronic Lymphocytic (CLL)
- Lung Cancer, Non-small Cell (NSCLC)
- Lymphoma, Hodgkin (HL)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Melanoma, Skin
- Ovarian and Primary Peritoneal Cancer
- Renal Cell Carcinoma (RCC)
- Renal Pelvis and Ureter Cancer
- Urethral Cancer
- Uterine Cancer (Parent)
- Waldenstrom’s Macroglobulinemia

Research

Starting Monday, June 10, 2024, Sarah Cannon Research Institute will manage all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRI.DLEMRAlysts@scri.com.

Updates

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
				Other Changes
USOR 21527	X			
USOR 22124		X		
USOR 22181	X	X		<p>No longer available:</p> <ul style="list-style-type: none"> • USOR 22181 Etrumadenant (PO; Daily) + Zimberelimab + Domvanalimab Q21D • USOR 22181 Etrumadenant (PO; Daily) + Zimberelimab Q21D <p>Now available: USOR 22181 Zimberelimab + Sacituzumab Govitecan D1,8 Q21D</p>

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
				Other Changes
USOR 22258	X			
USOR 23055	X			
USOR 23078	X			
USOR 23094	X			
USOR 23095		X		
USOR 23116	X			
USOR 23129	X			Now available: USOR 23129 Arm A ONC-392 + Lutetium Lu 177 vipivotide tetraxetan Q42D
USOR 23228	X			
USOR 23229	X	X		

Billing & HCPCS Codes

Updates

Medication	HCPCS Codes
Docetaxel	J9999 per 80 mg
Secukinumab IV	J3590 per 125 mg
Tocilizumab-aazg IV (Tyenne)	J3590 per <ul style="list-style-type: none"> • 80 mg • 200 mg • 400 mg
Tc-99m-sod pyroph IV (Technescan Pyp IV)	Q9969 per 1 dose
Nogapendekin alfa inbakicept-pmln Intravesical	J9999 per 400 mcg

NDC to HCPCS Crosswalk

Additions

Medication (Brand)	HCPCS Code	NDC
Risperidone (Rykindo)	J2801 per 0.5 mg	<ul style="list-style-type: none">• 72526020201• 72526020301• 72526010311• 72526010211• 72526010411• 72526020401